Adn 138
| Code | Size | Price |
|---|
| TAR-T29665-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Adn 138 is a bioactive chemical.
CAS:
99434-90-9
Formula:
C13H9ClN2O4
Molecular Weight:
292.68
Purity:
0.98
SMILES:
Clc1cc2c3N(CCOc3c1)C(=O)C21CC(=O)NC1=O
References
1. Wrobel J, Dietrich A, Woolson SA, Millen J, McCaleb M, Harrison MC, Hohman TC, Sredy J, Sullivan D. Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents. J Med Chem. 1992 Nov 27;35(24):4613-27. PubMed PMID: 1469692.
2. Hirata Y, Okada K. Relation of Na+, K(+)-ATPase to delayed motor nerve conduction velocity: effect of aldose reductase inhibitor, ADN-138, on Na+, K(+)-ATPase activity. Metabolism. 1990 Jun;39(6):563-7. PubMed PMID: 2161992.
3. Akagi Y, Ikebe H, Terubayashi H, Takahashi Y, Tsuji T. [Morphological classification of the prevention by aldose reductase inhibitor of rat galactosemic cataract]. Nippon Ganka Gakkai Zasshi. 1989 Apr;93(4):494-500. Japanese. PubMed PMID: 2508449.
4. Segawa M, Hirata Y, Fujimori S, Okada K. The development of electroretinogram abnormalities and the possible role of polyol pathway activity in diabetic hyperglycemia and galactosemia. Metabolism. 1988 May;37(5):454-60. PubMed PMID: 3285132.